{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 401667456
| IUPAC_name = ''N''-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- ''N''-(2-pyridyl)cyclohexanecarboxamide
| synonyms =  
| image = WAY-100,635.png
| width = 200
<!--Clinical data-->
| tradename =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 146714-97-8
| PubChem = 5684
| IUPHAR_ligand = 80
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 31354
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 5482
<!--Chemical data-->
| C=25 | H=34 | N=4 | O=2
| molecular_weight = 422.56 g/mol
| smiles = COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = SBPRIAGPYFYCRT-UHFFFAOYSA-N
}}

'''WAY-100,635''' is a [[piperazine]] [[drug]] and research chemical widely used in scientific studies. It was originally believed to act as a selective [[5-HT1A|5-HT<sub>1A</sub>]] [[receptor antagonist]], but subsequent research showed that it also acts as [[Efficacy#Pharmacology|potent]] [[full agonist]] at the [[D4 receptor|D<sub>4</sub>]] receptor.<ref>{{Cite journal | author = C. A. Fornal, C. W. Metzler, R. A. Gallegos, S. C. Veasey, A. C. McCreary and B. L. Jacobs | title = WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135 | journal = [[The Journal of Pharmacology and Experimental Therapeutics]] | volume = 278 | issue = 2 | pages = 752&ndash;762 | year = 1996 | url = http://jpet.aspetjournals.org/cgi/content/abstract/278/2/752 | pmid = 8768728 }}</ref><ref>{{Cite journal | author = Benjamin R. Chemel, Bryan L. Roth, Blaine Armbruster, Val J. Watts and [[David E. Nichols]] | title = WAY-100635 is a potent dopamine D4 receptor agonist | journal = [[Psychopharmacology (journal)|Psychopharmacology]] |date=October 2006 | volume = 188 | issue = 2 | pages = 244–251 | pmid = 16915381 | url = http://www.springerlink.com/content/vt36125287348028/  | doi = 10.1007/s00213-006-0490-4
}}</ref><ref name="pmid19179855">{{cite journal |vauthors=Marona-Lewicka D, Nichols DE |title=WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation |journal=Behav Pharmacol |volume=20 |issue=1 |pages=114–8 |year=2009 |pmid=19179855 |doi=10.1097/FBP.0b013e3283242f1a |url=}}</ref> It is sometimes referred to as a [[silent antagonist]] at the former receptor.<ref>{{Cite journal | author = A. Fletcher, E. A. Forster, D. J. Bill, G. Brown, I. A. Cliffe, J. E. Hartley, D. E. Jones, A. McLenachan, K. J. Stanhope, D. J. Critchley, K. J. Childs, V. C. Middlefell, L. Lanfumey, R. Corradetti, A. M. Laporte, H. Gozlan, M. Hamon & C. T. Dourish | title = Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist | journal = [[Behavioural Brain Research]] | volume = 73 | issue = 1–2 | pages = 337–53| year = 1996 | pmid = 8788530 | doi = 10.1016/0166-4328(96)00118-0 }}</ref> It is closely related to [[WAY-100,135]].

In light of its only recently discovered [[dopaminergic]] activity, conclusions drawn from studies that employed WAY-100635 as a selective 5-HT<sub>1A</sub> antagonist may need to be re-evaluated.

== Human PET studies ==
In human PET studies WAY-100,635 shows high binding in the [[cerebral cortex]], [[hippocampus]], [[raphe nucleus]] and [[amygdaloid nucleus]], while lower in [[thalamus]] and [[basal ganglia]].<ref>{{Cite journal
|author1=Hiroshi Ito, Christer Halldin  |author2=Lars Farde
 |lastauthoramp=yes | title = Localization of 5-HT<sub>1A</sub> receptors in the living human brain using &#91;carbonyl-<sup>11</sup>C&#93;WAY-100635: PET with anatomic standardization technique
| journal = [[Journal of Nuclear Medicine]]
| volume = 40
| issue = 1
| pages = 102–109
| date=January 1999
| pmid = 9935065
| url = http://jnm.snmjournals.org/cgi/content/abstract/40/1/102
}}</ref>
One study described a single case with relatively high binding in the cerebellum.<ref>{{Cite journal
| author = Jussi Hirvonen, Jaana Kajander, Topias Allonen, Vesa Oikonen, Kjell Nagren & Jarmo Hietala
| title = Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and &#91;''carbonyl''-<sup>11</sup>C&#93;WAY-100635&mdash;considerations on the validity of cerebellum as a reference region
| journal = [[Journal of Cerebral Blood Flow and Metabolism]]
| volume = 27
| issue = 1
| pages = 185–185
| date=January 2007
| doi = 10.1038/sj.jcbfm.9600326
| pmid = 16685258
}}</ref>

In relating its binding to subject variables one Swedish study found WAY-100,635 binding in [[raphe]] brain region correlating with [[self-transcendence]] and spiritual acceptance [[personality trait]]s.<ref name="BorgJ2003Serotonin">{{Cite journal
|author1=Jacqueline Borg |author2=Bengt Andrée |author3=Henrik Soderstrom |author4=Lars Farde | title = The Serotonin System and Spiritual Experiences
| journal = [[American Journal of Psychiatry]]
| volume = 160
| issue  = 11
| date=November 2003
| pages = 1965&ndash;1969
| url = http://ajp.psychiatryonline.org/cgi/content/full/160/11/1965
| doi = 10.1176/appi.ajp.160.11.1965
| pmid=14594742
}}</ref>
WAY-100,635 binding has also been assessed in connection with [[clinical depression]], where there has been disagreement about the presence and direction of the 5-HT<sub>1A</sub> receptor binding.<ref>{{Cite journal
| author = Wayne C. Drevets, Michael E. Thase, Eydie L. Moses-Kolko, Julie Price, Ellen Frank, David J. Kupfer and Chester Mathis
| title = Serotonin-1A receptor imaging in recurrent depression: replication and literature review
| journal = [[Nuclear Medicine and Biology]]
| date=October 2007 
| volume = 34
| issue = 7
| pages = 865&ndash;877
| pmid = 17921037 
| doi  = 10.1016/j.nucmedbio.2007.06.008
| pmc = 2702715 
}}</ref>
In healthy subjects WAY-100,635 binding has been found to decline with [[aging|age]],<ref name="TauscherJ2001Serotonin">{{Cite journal
| author = Johannes Tauscher, N. Paul L. G. Verhoeff, Bruce K. Christensen, Doug Hussey, Jeffrey H. Meyer, Alex Kecojevic, Mahan Javanmard, Siegfried Kasper  and Shitij Kapur
| title = Serotonin 5-HT<sub>1A</sub> Receptor Binding Potential Declines with Age as Measured by [<sup>11</sup>C]WAY-100635 and PET
| journal = [[Neuropsychopharmacology (journal)|Neuropsychopharmacology]]
| volume = 24
| issue = 5
| date=May 2001
| pages = 522&ndash;530
| doi = 10.1016/S0893-133X(00)00227-X
}}</ref>
&mdash; though not all studies have found this relationship.<ref name="RabinerE2002Database">{{Cite journal
|author1=Rabiner EA |author2=Messa C |author3=Sargent PA |author4=Husted-Kjaer K |author5=Montgomery A |author6=Lawrence AD |author7=Bench CJ |author8=Gunn RN |author9=Cowen P |author10=Grasby PM. | title = A database of [<sup>11</sup>C]WAY-100635 binding to 5-HT<sub>1A</sub> receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables
| journal = [[NeuroImage]]
| date=March 2002
| volume = 15
| issue = 3
| pages = 620&ndash;632
| pmid = 11848705
| doi = 10.1006/nimg.2001.0984 
}}</ref><ref  name="ParseyR2002Effects">{{Cite journal
|author1=R. V. Parsey |author2=M. A. Oquendo |author3=N. R. Simpson |author4=R. T. Ogden |author5=R. Van Heertum |author6=V. Arango V |author7=J. J. Mann | title  = Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635
| journal = [[Brain Research]]
| date=November 2002
| volume = 954
| issue = 2
| pages = 173&ndash;182
| pmid = 12414100
| doi  = 10.1016/S0006-8993(02)03243-2
}}</ref>

{| class="wikitable" 
|+ Human WAY-100635 binding neuroimaging studies (patients compared to healthy control subjects).
|-
! What !! Result !! Subjects !! Ref.
|-
| [[Aging|Age]]
| Global decrease and particularly in [[parietal cortex]] and [[dorsolateral prefrontal cortex]]
| 19
| <ref name="TauscherJ2001Serotonin"/>
|-
| [[Aging|Age]]
| No correlation found
| 61
| <ref name="RabinerE2002Database"/>
|-
| [[Aging|Age]]
| No correlation detected
| 25
| <ref name="ParseyR2002Effects"/>
|-
| [[Sex]]
| Higher binding in females
| 25
| <ref name="ParseyR2002Effects"/>
|-
| [[Temperament and Character Inventory|TCI]] [[self-transcendence]] and [[spiritual acceptance]] [[personality trait]]s
| Positive correlation in [[raphe nucleus|raphe]] region
| 15 males
| <ref name="BorgJ2003Serotonin"/>
|-
| Lifetime [[aggression]]
| Negative correlation
| 25
| <ref name="ParseyR2002Effects"/>
|-
| [[MADAM]] [[binding potential]] ([[serotonin transporter]] binding)
| Positive correlation in the [[raphe nuclei]] and [[hippocampus]]
| 12 males
| <ref>{{Cite journal
| author = Johan Lundberg, Jacqueline Borg, Christer Halldin and Lars Farde
| title = A PET study on regional coexpression of 5-HT<sub>1A</sub> receptors and 5-HTT in the human brain
| journal = [[Psychopharmacology (journal)|Psychopharmacology]]
| volume = 195
| issue = 3
| date=December 2007
| doi = 10.1007/s00213-007-0928-3
| pages = 425&ndash;433
}}</ref>
|-
! Genetic variation !! Result !! Subjects !! Ref.
|-
| [[HTR1A]].[[rs6295|(-1018)C>G]] [[Polymorphism (biology)|polymorphism]]
| No difference found
| 35
| <ref name="DavidS2005Functional">{{Cite journal
| author = Sean P. David, Naga Venkatesha Murthy, Eugenii A. Rabiner, Marcus R. Munafó, Elaine C. Johnstone, Robyn Jacob, Robert T. Walton & Paul M. Grasby
| title = A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans
| journal = [[The Journal of Neuroscience]]
| date=March 2005
| volume = 25
| issue = 10
| pages = 2586&ndash;2590
| url = http://www.jneurosci.org/cgi/content/full/25/10/2586
| pmid = 15758168
| doi = 10.1523/JNEUROSCI.3769-04.2005
| pmc = 1942077
}}</ref>
|-
| [[serotonin transporter|SERT]].[[5-HTTLPR]] polymorphism
| Lower binding in "all brain regions" for SS or SL genotypes compared to LL
| 35
| <ref name="DavidS2005Functional"/>
|-
! Disease !! Result !! Subjects !! Ref.
|-
| Depressive (with primary, recurrent, familial mood disorders)
| Reduction in [[raphe nucleus]] and [[mesiotemporal cortex]]
| 12+8 
| <ref>{{Cite journal
| author = Wayne C. Drevets, Ellen Frank, Julie C. Price, David J. Kupfer, Daniel Holt, Phil J. Greer, Yiyun Huang, Clara Gautier and Chester Mathis
| title = Pet imaging of serotonin 1A receptor binding in depression
| journal = [[Biological Psychiatry]]
| volume = 46
| issue = 10
| date=November 1999
| pages = 1375&ndash;1387
| doi = 10.1016/S0006-3223(99)00189-4
| pmid=10578452
}}</ref>
|-
| [[Major depressive disorder]] (medicated and unmedicated)
| Reduction in "many of the regions examined"
| 25+18
| <ref>{{Cite journal
|author1=Peter A. Sargent |author2=Karen Husted Kjaer |author3=Christopher J. Bench |author4=Eugenii A. Rabiner |author5=Cristina Messa |author6=Jeff Meyer |author7=Roger N. Gunn |author8=Paul M. Grasby |author9=Philip J. Cowen | title = Brain Serotonin<sub>1A</sub> Receptor Binding Measured by Positron Emission Tomography With [<sup>11</sup>C]WAY-100635. Effects of Depression and Antidepressant Treatment
| journal = Archives of General Psychiatry
| volume = 57
| issue = 2
| pages = 174&ndash;180
| date=February 2000
| url = http://archpsyc.highwire.org/cgi/content/abstract/57/2/174
| doi = 10.1001/archpsyc.57.2.174
}}</ref>
|-
| [[Panic disorder]] in treated and untreated patients
| Reducing in binding in [[raphe]] in both treated and untreated. Reduced binding in global postsynaptic regions for untreated, while no or little reduction for treated.
| 9+7+19
| <ref>{{Cite journal
| author = Jon R. Nash, Peter A. Sargent, Eugenii A. Rabiner, Sean D. Hood, Paul M. Grasby & David J. Nutt
| title = Serotonin 5-HT<sub>1A</sub> receptor binding in people with panic disorder: positron emission tomography study
| journal = [[The British Journal of Psychiatry]]
| year = 2008
| volume = 193
| pages = 229&ndash;234
| doi = 10.1192/bjp.bp.107.041186
| url = http://bjp.rcpsych.org/cgi/content/full/193/3/229
| pmid=18757983
| issue=3
}}</ref>
|-
| [[Alzheimer disease]]
| Decrease in right [[medial temporal cortex]]
| 10+10
| <ref>{{Cite journal
| author = Krista L. Lanctôt, Doug F. Hussey, Nathan Herrmann, Sandra E. Black, Pablo M. Rusjan, Alan A. Wilson, Sylvain Houle, Nicole Kozloff, Nicholaas Paul L.G. Verhoeff, and Shitij Kapur
| title =  A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease
| journal = [[American Journal of Geriatric Psychiatry]]
| date=October 2007
| volume = 15
| issue = 10
| pages = 888&ndash;898
| pmid = 17567932
| url = http://ajgponline.org/cgi/content/abstract/15/10/888
| doi = 10.1097/JGP.0b013e3180488325
}}</ref>
|}

===Radioligands===
Labeled with the [[radioisotope]] [[carbon-11]] it is used as a [[radioligand]] in [[positron emission tomography]] (PET) studies to determine [[neuroreceptor]] binding in the [[brain]].<ref>{{Cite journal
| author = Victor W. Pike, Julie A. McCarron, Adriaan A. Lammerstma, Susan P. Hume, Keith Poole, Paul M. Grasby, Andrea Malizia, Ian A. Cliffe, Allan Fletcher & Christopher J. Bench
| title = First delineation of 5-HT<sub>1A</sub> receptors in human brain with PET and [<sup>11</sup>C]WAY-100635
| journal = [[European Journal of Pharmacology]]
| volume = 283
| date=September 1995
| pages = R1–R3
| doi = 10.1016/0014-2999(95)00438-Q|issue=s 1-3
| pmid=7498295
}}</ref>
WAY-100,635 may be labeled in different ways with carbon-11: 
As [carbonyl-<sup>11</sup>C]WAY-100,635 or [O-methyl-<sup>11</sup>C]WAY-100,635, with [carbonyl-<sup>11</sup>C]WAY-100635 regarded as "far superior".<ref>{{Cite journal
| author = Victor W. Pike, Julie A. McCarron, Adriaan A. Lammertsma, Safiye Osman, Susan P. Hume, Peter A. Sargent, Christopher J. Bench, Ian A. Cliffe, Alan Fletcher and Paul M. Grasby
| title = Exquisite delineation of 5-HT<sub>1A</sub> receptors in human brain with PET and [carbonyl-<sup>11</sup>C]WAY-100635
| journal = [[European Journal of Pharmacology]]
| volume = 301
| issue = 1–3
| date=April 1996
| pages = R5–R7
| doi = 10.1016/0014-2999(96)00079-9 
}}</ref>
Labeled with [[tritium]] WAY-100,635 may also be used in [[autoradiography]].<ref>{{Cite journal
| author = Susan P. Hume, Sharon Ashworth, Jolanta Opacka-Juffry, Randal G. Ahier, Adriaan A. Lammertsma, Victor W. Pike, Ian A. Cliffe, Allan Fletcher and Alan C. White
| title = Evaluation of [''O-methyl''-<sup>3</sup>H]WAY-100635 as an in vivo radioligand for 5-HT<sub>1A</sub> receptors in rat brain
| journal = [[European Journal of Pharmacology]]
| volume = 271
| issue = 2–3
| date=December 1994
| pages = 515&ndash;523
| doi = 10.1016/0014-2999(94)90813-3
}}</ref>
WAY-100,635 has higher 5-HT1A affinity than [[8-OH-DPAT]].<ref>{{Cite journal
| author = P. W. J. Burnet, S. L. Eastwood & P. J. Harrison
| title = [<sup>3</sup>H]WAY-100635 for 5-HT<sub>1A</sub> receptor autoradiography in human brain: a comparison with [<sup>3</sup>H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia
| journal = [[Neurochemistry International]]
| date=June 1997
| volume = 30
| issue = 6
| pages = 565&ndash;574
| pmid = 9152998
| doi = 10.1016/S0197-0186(96)00124-6
}}</ref>

==Other actions==
WAY-100,635 has also been found to increase the analgesic effects of [[opioid]] drugs in a dose-dependent manner, in contrast to 5-HT<sub>1A</sub> agonists such as [[8-OH-DPAT]] which were found to reduce opioid analgesia.<ref name="pmid15109976">{{cite journal |vauthors=Bardin L, Colpaert FC |title=Role of spinal 5-HT(1A) receptors in morphine analgesia and tolerance in rats |journal=European Journal of Pain |volume=8 |issue=3 |pages=253–61 |date=June 2004 |pmid=15109976 |doi=10.1016/j.ejpain.2003.09.002 |url=}}</ref><ref name="pmid17393145">{{cite journal |vauthors=Berrocoso E, De Benito MD, Mico JA |title=Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats |journal=Psychopharmacology |volume=193 |issue=1 |pages=97–105 |date=July 2007 |pmid=17393145 |doi=10.1007/s00213-007-0761-8 |url=}}</ref> However, since 5-HT<sub>1A</sub> agonists were also found to reduce opioid-induced [[respiratory depression]] and WAY-100,635 was found to block this effect,<ref name="pmid10640309">{{cite journal |vauthors=Sahibzada N, Ferreira M, Wasserman AM, Taveira-DaSilva AM, Gillis RA |title=Reversal of morphine-induced apnea in the anesthetized rat by drugs that activate 5-hydroxytryptamine(1A) receptors |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=292 |issue=2 |pages=704–13 |date=February 2000 |pmid=10640309 |doi= |url=}}</ref> it is likely that 5-HT<sub>1A</sub> antagonists might worsen this side effect of opioids. Paradoxically, chronic administration of the very high efficacy 5-HT<sub>1A</sub> agonist [[befiradol]] results in potent analgesia following an initial period of [[hyperalgesia]], an effect most likely linked to desensitisation and/or downregulation of 5-HT<sub>1A</sub> receptors (i.e. analogous to a 5-HT<sub>1A</sub> antagonist-like effect).<ref name="pmid15528450">{{cite journal |vauthors=Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC |title=Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-<nowiki/>{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=312 |issue=3 |pages=1034–42 |date=March 2005 |month= |pmid=15528450 |doi=10.1124/jpet.104.077669 |url=}}</ref><ref name="pmid16921393">{{cite journal |vauthors=Assié MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A |title=Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat |journal=British Journal of Pharmacology |volume=149 |issue=2 |pages=170–8 |date=September 2006 |pmid=16921393 |pmc=2013794 |doi=10.1038/sj.bjp.0706859 |url=}}</ref><ref name="pmid18809418">{{cite journal |vauthors=Buritova J, Berrichon G, Cathala C, Colpaert F, Cussac D |title=Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study |journal=Neuropharmacology |volume=56 |issue=2 |pages=350–61 |date=February 2009 |pmid=18809418 |doi=10.1016/j.neuropharm.2008.09.004 |url=}}</ref>

== See also ==
* [[Binding potential]]
* Other radioligands for the serotonin system:
** [[Altanserin]]
** [[DASB]]
** [[Mefway]]

== External links ==
* {{Cite web
| url = http://www.turkupetcentre.net/analysis/doc/tracer/way100635.html
| title  = Quantification of (carbonyl-<sup>11</sup>C)WAY-100635 PET studies
| author = Vesa Oikonen
| publisher = Turku PET center
| year = 2007
}}

== References ==
{{Reflist|2}}

{{Serotonergics}}
{{Dopaminergics}}
{{Piperazines}}

[[Category:Dopamine agonists]]
[[Category:Piperazines]]
[[Category:Phenol ethers]]
[[Category:Carboxamides]]
[[Category:Pyridines]]
[[Category:Serotonin antagonists]]